guy kleinmann , roy alon2,ehud i. assia · guy kleinmann1, roy alon2,ehud i. assia2 [1] kaplan...
TRANSCRIPT
![Page 1: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/1.jpg)
Financial disclosure: The study was supported by a grant from Hanita Lenses, Israel
Dr. Kleinmann and Prof. Assia are consultants for Hanita Lenses, Israel
Guy Kleinmann1, Roy Alon2,Ehud I. Assia2
[1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel
![Page 2: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/2.jpg)
PCO is still a problem, mainly with premium IOLs
Last year we presented our preliminary favorable PCO prevention results while using the Open Capsule Device
![Page 3: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/3.jpg)
To investigate the ability of the PID to prevent PCO using hydrophilic and hydrophobic materials and IOLs
![Page 4: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/4.jpg)
Dimensions for rabbit trial:
Total Diameter: 11 mm
Device height: 1.5 mm
Hydrophilic and
hydrophobic rings *patent pending
![Page 5: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/5.jpg)
Both IOLs:
Total Diameter: 13 mm
Optic diameter: 6 mm
3600 square edge
Tecnis (AMO)
Hydrophobic IOL
SeeLens AF (Hanita Lenses)
Hydrophilic IOL
![Page 6: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/6.jpg)
36 NZW rabbit eyes were divided into six groups and implanted, after lens removal, as following:
Following tests were performed: Slit Lamp and Miyake Apple evaluation at 6 weeks
Histopathological evaluation
Hydrophobic IOL (Tecnis, AMO)
Hydrophilic IOL (SeeLens, Hanita Lenses)
6 eyes 6 eyes Control (IOL only)
6 eyes 6 eyes Hydrophilic ring (Hanita Lenses)
6 eyes 6 eyes Hydrophobic ring (Hanita Lenses)
![Page 7: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/7.jpg)
Implantation of hydrophilic ring was easier, and can be compared to standard IOL implantation
Insertion of IOL haptics into the PID groove was not automatic and required manipulations
Ovalization due to large
diameter of the ring
The capsule remained open
![Page 8: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/8.jpg)
Control Ring
75% less PCO compared to control
Hydrophobic IOL Hydrophilic IOL
3.1 ± 1.2 2.7 ± 1.1 Control (IOL only)
1.1 ± 0.9 0.6 ± 0.6 Hydrophilic ring**
0.6 ± 0.9 0.7 ± 0.7 Hydrophobic ring**
PCO score*:
(severe)4 (absent) to 0 [*] **P-value<0.05
![Page 9: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/9.jpg)
Control Ring
Significant reduction in Soemmering’s ring development in test groups
![Page 10: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/10.jpg)
Region of Soemmering’s ring coverage was manually marked and analyzed using Matlab software
Soemmering’s ring
Region of interest (bag excluding optical zone)
![Page 11: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/11.jpg)
80% less Soemmering’s ring coverage compared to control
Hydrophobic IOL Hydrophilic IOL
52 ± 8 mm2 (95%) 52 ± 10 mm2 (92%) Control (IOL only)
13.6 ± 7 mm2 (22%) 9.6 ± 6 mm2 (17%) Hydrophilic ring
11 ± 11 mm2 (15%) 14.6 ± 9 mm2 (22%) Hydrophobic ring
Soemmering’s ring coverage *:
% (full coverage)100% (clear capsule) to 0[*]
Control Ring
![Page 12: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/12.jpg)
Control group:
![Page 13: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/13.jpg)
Control group:
![Page 14: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/14.jpg)
Test group:
![Page 15: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/15.jpg)
Test group:
![Page 16: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/16.jpg)
Test group:
![Page 17: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/17.jpg)
Test group: atypical observation
![Page 18: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/18.jpg)
Hydrophobic IOL Hydrophilic IOL Histological PCO grading
2.8 2.2 Control (IOL only)
0.7 (75%↓) 1.3 (35%↓) Hydrophilic ring
0.6 (79%↓) 0.6 (73%↓) Hydrophobic ring
*Grade 0 - no LEC proliferation, grade 4 – above 10 layers of LEC proliferation
![Page 19: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/19.jpg)
Encouraging PCO prevention results for both ring materials
No significant difference between hydrophilic and hydrophobic IOLs
Our results suggested primary PCO prevention
Mechanism not completely clear: Open capsule?
Windows in the PID design – prevention of ischemia?
![Page 20: Guy Kleinmann , Roy Alon2,Ehud I. Assia · Guy Kleinmann1, Roy Alon2,Ehud I. Assia2 [1] Kaplan Medical Center, Rehovot, Israel [2] Meir Medical Center, Kfar-Saba, Israel](https://reader034.vdocuments.site/reader034/viewer/2022050323/5f7c90db067d4c24af7cdc67/html5/thumbnails/20.jpg)
Thank you!